Kindred Biosciences Overview

  • Founded
  • 2012

Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 70

Employees

  • Latest Deal Type
  • Grant

  • Financing Rounds
  • 6

  • Investments
  • 1

Kindred Biosciences General Information

Description

Kindred Biosciences Inc is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. The company identifies targets that have already demonstrated safety and efficacy in humans and develop therapeutics based on these validated targets for dogs and cats. It has a pipeline of novel biologics in development across many therapeutic classes, alongside biologics manufacturing capabilities and a broad intellectual property portfolio.

Contact Information

Website
www.kindredbio.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Other Services (B2C Non-Financial)
Biotechnology
Acquirer
Elanco Animal Health
Primary Office
  • 1555 Bayshore Highway
  • Suite 200
  • Burlingame, CA 94010
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kindred Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kindred Biosciences‘s full profile, request access.

Request a free trial

Kindred Biosciences Patents

  • 91

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 4

    Granted

  • 14

    Pending

  • 000

    Expiring in next 12 mo

Kindred Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021401815-A1 Tnf alpha and ngf antibodies for veterinary use Pending 18-Dec-2020 0000000000
CA-3202331-A1 Tnf alpha and ngf antibodies for veterinary use Pending 18-Dec-2020 0000000000
EP-4138914-A1 Long-acting anti-il31 antibodies for veterinary use Pending 22-Apr-2020 0000000000
AU-2021259785-A1 Il4/il13 receptor molecules for veterinary use Pending 22-Apr-2020 00000000000
CA-3173927-A1 Il4/il13 receptor molecules for veterinary use Pending 22-Apr-2020 C07K14/7155
To view Kindred Biosciences’s complete patent history, request access »

Kindred Biosciences Executive Team (7)

Name Title Board Seat Contact Info
Wendy Wee Chief Financial Officer & Secretary, Administration
You’re viewing 1 of 7 executive team members. Get the full list »

Kindred Biosciences Board Members (7)

Name Representing Role Since
000000 000000 Kindred Biosciences Co-Founder & Board Member 000 0000
You’re viewing 1 of 7 board members. Get the full list »

Kindred Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kindred Biosciences Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kindred Biosciences‘s full profile, request access.

Request a free trial

Kindred Biosciences Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 00 21-Jun-2017 000000000 00.000 Buildings and Property 000000 00
To view Kindred Biosciences’s complete investments history, request access »